Rhythm Technologies (Nasdaq:IRTC) announced that the FDA granted 510(k) clearance for Zio AT design modifications and ...

根据最近向美国证券交易委员会(SEC)提交的8-K文件,医疗设备和服务提供商iRhythm Technologies, Inc.对其公司治理结构进行了重大修改。这家以外科和医疗器械板块工作而闻名的公司修订了其2016年股权激励计划,并更新了行为准则。 2024年11月7日,在薪酬和人力资本管理委员会的建议下,iRhythm董事会批准了对2016年股权激励计划的修订,取消了可发行股份数量的自动年度增 ...

The Japanese Pharmaceutical and Medical Device Agency (PMDA) has approved iRhythm Technologies’ Zio ECG monitoring system, an ...

However, the company said it will delay a submission for its next-generation Zio cardiac monitoring system until remediation ...

Application error: a client-side exception has occurred (see the browser console for more information).

旧金山——根据最近的SEC文件显示，iRhythm Technologies, Inc. (NASDAQ:IRTC)的总裁兼首席执行官Blackford Quentin S.最近出售了他持有的该公司大量股份。Blackford于2024年11月4日以平均每股77.41美元的价格出售了16,145股普通股，总价值约125万美元。

The Food and Drug Administration cleared prior design modifications for iRhythm Technologies’ Zio AT wearable cardiac monitoring system in the first of two 510(k) submissions to the agency tied ...

Quentin Blackford, President and CEO of iRhythm, stated, "This clearance is related to modifications and certain enhancements to our Zio AT device previously made via letter to file and has been a ...

In new guidance, the health technology assessment (HTA) agency has recommended iRhythm’s Zio XT service for detecting abnormal heart rhythms – provided NHS organisations that deploy it collect ...

iRhythm's stock surged over 20% today after the FDA cleared its 510(k) submission for the Zio AT device, despite ongoing regulatory challenges. The company still faces significant hurdles ...

SAN FRANCISCO - iRhythm Technologies, Inc. (NASDAQ:IRTC), a company specializing in digital healthcare solutions, announced today that it has received clearance from the U.S. Food and Drug ...

Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) rose sharply in today's pre-market trading after the company announced ...